Cognitive risks of anticholinergics in the elderly

Aging Health

Volumn 9, Issue 2, 2013, Pages 159-166

  Gerretsen, Philip ^a,b   Pollock, Bruce G ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

anticholinergic; anticholinergic adverse effect; anticholinergic drug; cognition; elderly; geriatric; later life

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; BROMPHENIRAMINE; CARBINOXAMINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; IMIPRAMINE; LOXAPINE; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROMETHAZINE; PROTRIPTYLINE; QUETIAPINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIMIPRAMINE; UNINDEXED DRUG;

AGING; ANTICHOLINERGIC EFFECT; ANTICHOLINERGIC SYNDROME; APOE GENE; CAUSAL ATTRIBUTION; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DRUG MONITORING; DRUG RESPONSE; GENE; GENOTYPE; HUMAN; NERVE DEGENERATION; NEUROTRANSMISSION; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOMATOLOGY;

EID: 84875940954     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.13.14     Document Type: Review

References (50)

1. Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium. Am. J. Psychiatry 149(10), 1393-1394 (1992
2. Chew ML, Mulsant BH, Pollock BG et al. Anticholinergic activity of 107 medications commonly used by older adults. J. Am.Geriatr. Soc. 56(7), 1333-1341 (2008
3. Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch. Intern. Med. 161(8), 1099-1105 (2001
4. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: A current perspective on use and safety. Expert Opin. Drug Saf. 10(5), 751-765 (2011
5. Modi A, Weiner M, Craig BA, Sands LP, Rosenman MB, Thomas J 3rd. Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. J. Am. Geriatr. Soc. 57(7), 1238-1244 (2009
6. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: Relationship with cognitive performance. Arch. Gen. Psychiatry 60(2), 198-203 (2003
7. Gerretsen P, Pollock BG. Rediscovering adverse anticholinergic effects. J. Clin. Psychiatry 72(6), 869-870 (2011
8. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 12(3), 232-246 (2007
9. Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nat. Rev. Neurosci. 6(1), 48-56 (2005
10. Mesulam MM. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 145, 67-78 (2004
11. Barak S. Modeling cholinergic aspects of schizophrenia: Focus on the antimuscarinic syndrome. Behav. Brain Res. 204(2), 335-351 (2009
12. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (2007 Edition). Canadian Pharmacists Association, ON, Canada (2007
13. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Am. J. Obstet. Gynecol. 187(1), 116-126 (2002
14. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87(9), 760-766 (2001
15. Schweitzer P, Mark H. The effect of atropine on cardiac arrhythmias and conduction. Part 2. Am. Heart J. 100(2), 255-261 (1980
16. Schweitzer P, Mark H. The effect of atropine on cardiac arrhythmias and conduction. Part 1. Am. Heart J. 100(1), 119-127 (1980
17. Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC. Sensitivity to antipsychotic drugs in older adults. Curr. Psychiatry Rep. 12(1), 28-33 (2010
18. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 221(2), 555-563 (2011
19. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur. J. Clin. Pharmacol. 60(2), 97-102 (2004
20. Wong DF, Wagner HN Jr, Dannals RF et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226(4681), 1393-1396 (1984
21. Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat. Rev. Neurosci. 7(1), 30-40 (2006
22. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163(2), 495-529 (2000
23. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558), 408-414 (1982
24. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: A review of recent evidence. Trends Neurosci. 14(6), 220-223 (1991
25. Mufson EJ, Ginsberg SD, Ikonomovic MD, Dekosky ST. Human cholinergic basal forebrain: Chemoanatomy and neurologic dysfunction. J. Chem. Neuroanat. 26(4), 233-242 (2003
26. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215(4537), 1237-1239 (1982
27. Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am. J. Geriatr. Psychiatry 13(6), 535-538 (2005
28. Rovner BW, David A, Lucas-Blaustein MJ, Conklin B, Filipp L, Tune L. Self-care capacity and anticholinergic drug levels in nursing home patients. Am. J. Psychiatry 145(1), 107-109 (1988
29. Cancelli I, Valentinis L, Merlino G, Valente M, Gigli GL. Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease. Clin. Pharmacol. Ther. 84(1), 63-68 (2008
30. Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am. J. Geriatr. Psychiatry 11(4), 458-461 (2003
31. Nebes R, Pollock BG, Mulsant BH et al. Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients. Psychopharmacol. Bulletin 33, 715-720 (1997
32. Cancelli I, Gigli GL, Piani A et al. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A population-based study. J. Clin. Psychopharmacol. 28(6), 654-659 (2008
33. Carriere I, Fourrier-Reglat A, Dartigues JF et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Arch. Intern. Med. 169(14), 1317-1324 (2009
34. Aizenberg D, Sigler M, Weizman A, Barak Y. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: A 4-year case-control study. Int. Psychogeriatr. 14(3), 307-310 (2002
35. Nebes RD, Pollock BG, Halligan EM, Kirshner MA, Houck PR. Serum anticholinergic activity and motor performance in elderly persons. J. Gerontol. A Biol. Sci. Med. Sci. 62(1), 83-85 (2007
36. Nebes RD, Pollock BG, Halligan EM, Houck P, Saxton JA. Cognitive slowing associated with elevated serum anticholinergic activity in older individuals is decreased by caffeine use. Am. J. Geriatr. Psychiatry 19(2), 169-175 (2010
37. Nebes RD, Pollock BG, Perera S, Halligan EM, Saxton JA. The greater sensitivity of elderly APOE epsilon4 carriers to anticholinergic medications is independent of cerebrovascular disease risk. Am. J. Geriatr. Pharmacother. 10(3), 185-192 (2012
38. Uusvaara J, Pitkala KH, Tienari PJ, Kautiainen H, Tilvis RS, Strandberg TE. Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: A cross-sectional study. J. Am. Geriatr. Soc. 57(3), 427-431 (2009
39. Campbell NL, Boustani MA, Lane KA et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 75(2), 152-159 (2010
40. Mangoni AA, Van Munster BC, Woodman RJ, De Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am. J. Geriatr. Psychiatry doi:10.1097/JGP.0b013e3182546182 (2012) (Epub ahead of print
41. Hilmer SN, Mager DE, Simonsick EM et al. A drug burden index to define the functional burden of medications in older people. Arch. Intern. Med. 167(8), 781-787 (2007
42. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. J. Clin. Pharmacol. 46(12), 1481-1486 (2006
43. Kersten H, Molden E, Willumsen T, Engedal K, Wyller TB. Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br. J. Clin. Pharmacol. 75(3), 842-849 (2012
44. Kersten H, Molden E, Tolo IK, Skovlund E, Engedal K, Wyller TB. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: A randomized controlled trial. J. Gerontol. A Biol. Sci. Med. Sci. 68(3), 271-278 (2012
45. Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch. Gen. Psychiatry 37(3), 293-297 (1980
46. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: Decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 166(9), 1055-1062 (2009
47. Nishtala PS, Fois RA, Mclachlan AJ, Bell JS, Kelly PJ, Chen TF. Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. J. Clin. Pharmacol. 49(10), 1176-1184 (2009
48. Carnahan RM, Lund BC, Perry PJ, Pollock BG. A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacol. Bull. 36(2), 24-39 (2002
49. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8(2), 131-168 (2012
50. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 60(4), 616-631 (2012